The Food and Drug Administration announced on Dec. 11 that it has formally proposed letting companies add bemotrizinol to sunscreen.
“Based on FDA’s review of the data on the efficacy of bemotrizinol, FDA tentatively concludes that there is adequate evidence of the efficacy of bemotrizinol for use as an active ingredient in nonprescription sunscreen drug products intended for use in adults and children 6 months of age and older,” regulators said.
The review also analyzed safety studies that enrolled 484 adults and exposed them to bemotrizonal over three weeks. There were few adverse events such as sunburn and rashes reported, and no serious adverse events among the participants.
Scant data are available for children, but the FDA said that because the absorption rate is low, it does not think it needs to require additional studies in children.
Regulators are proposing to let bemotrizinol be added to sunscreen at concentrations up to 6 percent. The FDA’s proposal came in response to a 2024 request from a company called DSM Nutritional Products.
Regulators are accepting comments from the public on the proposed order. People can comment on Regulations.gov through the end of Jan. 26, 2026.
If at the end of the comment period regulators conclude that bemotrizinol is generally safe and effective in sunscreen, they will promulgate a new, final order.
Bemotrizinol is not currently allowed to be used in sunscreen sold in the United States. A number of other countries, including Australia, Canada, and nations in Europe, allow its addition to sunscreen.
The Environmental Working Group hailed the move.
“For years, Americans have been denied access to sunscreen ingredients that offer stronger UVA protection with fewer health concerns. Approving bemotrizinol would finally begin to close the gap between U.S. consumers and the rest of the world.”







